18 January 2022 - - US-based pharmaceutical company Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) has announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict, with 180 days of marketing exclusivity.

US sales of Vasostrict totaled USD890 m for the LTM ended September 30, 2021.

On December 15, 2021, the US Food and Drug Administration approved Eagle's abbreviated new drug application for vasopressin, a product that is indicated for use to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

Eagle was first-to-file an ANDA referencing Par Pharmaceutical, Inc.'s Vasostrict for the 20 units per ml presentation.

On August 31, 2021, the US District Court for the District of Delaware held that Eagle's proposed vasopressin product does not infringe any of the patents Par asserted against Eagle.

Par's appeal of the District Court's ruling remains pending, and Eagle will continue to vigorously defend against such appeal.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise.

Eagle's commercialized products include Ryanodex, Bendeka, Belrapzo, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.